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Ⅰ　Introduction
　As for the glossodynia which is the typical 
affection of the non- organic-pain of the maxilla-
facial area, the cause isn't clear yet.  In the 
ambulatory-practice, it is one of the affections 
most anxiously in the diagnosis and at the 
medical treatment. At meals, the tongue pain 
often reduces and it often disappears but daily, 
it appears something like the inflammatory 
diseases. Specifically, it experiences a lot of 
examples to occur more often and to complain to 
the woman of the convex experience which is in 
the cancer age of them as the cancer phobia, too. 
Therefore, it thinks that it places a glossodynia 
as so-called non organic chronic pain disease.
Ⅱ　Materials and Methods
　From 2013 in 3 years and half-year of the 
pasts, we treated with Escitalopram of SSRI 
for  50 examples ( 45 female and 5 male ) of the 
glossodynia which complained of the non-organic-
pain.  The evaluation used Visual Analogue 
Scale (VAS).
Ⅲ　Result
　Becoming VAS0 was 29 examples in 40 
examples to the 4th week. The half example did 
a remission rate within two weeks. Specifically, 
it did 2 examples by the remission within 1 
week.  Finally, we get the remission rate at 75 %. 
Ⅳ　Discussion
　Usually, the effect manifestation is recognized 
that it does the activation of the descending pain 
modulation system in SSRI or SNRI by the non-
organic-pain patient. We get the half example 
did a remission rate within two weeks. This 
result supports the common view to show an 
effect comparatively in short time at low dosage 
when using SSRI or SNRI to the chronic pain.
　While, the research by fMRI and PET became 
accomplished and it found the thing that the 
involvement of the system which secretes an 
endogenous-opioid peptide by the activation of 
the endogenic dopamine system is concerned. 
It reasoned by what action mechanism a 
dolor arrest was accomplished by prescribing 
Escitalopram which is SSRI at this article.
　Generally, in case of pain added to the human 
body, by that phasic dopamine which presents 
the transient firing of burst style like from the 
ventrotegmental area ( VTA ) of the midbrain is 
slipped in quantities, peptide of the endogenous-
opioids such as the β-endorphin is produced in 
the  nucleus accumbens ( NAc ) and the ventral 
pallidum ( VP ) and a pain is restrained 1). This 
9The Early Effect Onset of SSRI to the Non-Organic-Pain in the Mouth and Face Area
is the operation of the A10 nerve which is 
stretching an axis cylinder in NAc, or VP and 
at the mesolimbic dopamine system from VTA 
and is for peptide of the endogenous-opioids 
such as the β-endorphin to be secreted by the 
production through the mesolimbic dopamine 
system and for a pain to be restrained through 
the descending pain modulation system.
　By fMRI (functional magnetic resonance 
imaging) Hanba is reporting that the cerebral 
activity of NAc declines compared with 16 
chronic lumbar backache patient and 16 able-
bodied people, adding a heat stimulation 
repeatedly2). By the report which used adding 
PET in the pain stimulation a μ-opioid was 
secreted of the nucleuses such as the NAc, the 
amygdaloid body, the anterior cingulate gyrus, 
the frontal cortex, the thalamus is reported3)
　Actually, We knew that the dopamine which 
was confiscated from these as the main system 
of " the reward circuit " which relates to the 
higher brain dysfunction such as the emotion 
and the reward, the learning and the exercise in 
the past concerned  pain restraint deeply4,5).
Serotonin concentration is supposed to decline 
with the chronic stress and the fatigue like a 
mind and body. Also, the patient who complains 
of the chronic pain is often exposed to the 
chronic stress and the fatigue and there are not 
even among them few persons who present a 
depressed state.
　In the depressive state, it falls into a state of 
the serotonin lack at both of the dendrite and the 
synapse area and the serotonin receptor behind 
the presynapse and the synapse presents a state 
of the up-regulation. When prescribing SSRI, by 
the obstruction of the serotonin transporter, in 
the early stages of the prescribing, the serotonin 
in the somatodendritic area increases. Therefore, 
the increased serotonin restrains the isolation 
of the serotonin when it combines with the 
5HT1A receptor which is an autoreceptor on the 
somatodendritic of the presynapse and another 
5HT2A receptors of synapses on the dopamine 
nerve cell aren't activated. For glutamicacid 
in the brain stem through the 5HT2A receptor 
not to be released, inhibitory GABA, too, isn't 
released and prompts for the dopamine in 
the downstream corpus striatum. The opioid 
peptide of stimulating an accumbens nucleus by 
the dopamine which was liberated in this way 
through the mesolimbic dopamine system as 
phasic dopamine by the ventrotegmental area 
such as β-endorphin (Fig.1). It forwards the 
production of opioid peptide and a chronic pain 
is restrained through the μ opioid-receptor of 
the descending pain modulation system6).
Ⅴ　Conclusion
　We repor ted  because  we prescr ibed 
Escitalopram which is SSRI to 40 cases of 
glossodynia by the stress and supposed a 
theoretical background to the effect. As a 
result, the rise of the dopamine concentration 
is supposed to be gotten mainly in the A10 
nerve when prescribing Escitalopram for the 
non-organic-pain patient by it, and it supposes 
that the dopamine neural circuit which covers 
a limbic cortex and a basal ganglia, a midbrain 
and so on is made activation when prescribing 
and endogenous-opioid peptide is supposed to 
be secreted by it and it supposed a pain control 
to be attempted through the descending pain 
modulation system.
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Fig.1: The chronic pain disappearance in short time by Phasic Dopamine increase
